Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regdanvimab: First Approval
Yahiya Y. Syed
Drugs (2021) Vol. 81, Iss. 18, pp. 2133-2137
Open Access | Times Cited: 53

Showing 26-50 of 53 citing articles:

Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series
Cornelius Rau, Lorenz Auer‐Hackenberg, Hedwig E. Deubzer, et al.
The Pediatric Infectious Disease Journal (2022) Vol. 42, Iss. 2, pp. 125-129
Open Access | Times Cited: 8
Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
Haein Kim, Young Rock Jang, Ji Yeon Lee, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 4
Further Accelerating Biologics Development from DNA to IND: The Journey from COVID-19 to Non-COVID-19 Programs
Kee W. Tan, Pengfei Ji, Hang Zhou, et al.
Antibody Therapeutics (2024) Vol. 7, Iss. 1, pp. 96-104
Open Access | Times Cited: 1
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement
Julia E. Edgar, Stylianos Bournazos
Immunological Reviews (2024)
Open Access | Times Cited: 1
Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 supports its development as a potent, dose-saving inhaled therapy for COVID-19
Morgan D. McSweeney, Ian E. Stewart, Zach Richardson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Involvement of the STING signaling in COVID-19
Ruoxuan Xiao, Ao Zhang
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea
Jaehyun Jeon, Bum Sik Chin
Journal of Korean Medical Science (2022) Vol. 37, Iss. 48
Open Access | Times Cited: 7
Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study
Soyoon Hwang, Nan Young Lee, Eunkyung Nam, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 5, pp. 1037-1050
Open Access | Times Cited: 1
Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study
Susin Park, Nam Kyung Je, Dong Wan Kim, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19
Thomas R. Moench, Lakshmi Botta, Brian T. Farrer, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses
Hui Ting Lim, Boon Hui Kok, Chin Peng Lim, et al.
Biomedical Engineering Advances (2022) Vol. 4, pp. 100054-100054
Open Access | Times Cited: 6
Drug-drug interactions between COVID-19 drug therapies and antidepressants
Efstathia Davoutis, C Panou, Nikolina Stachika, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 937-950
Closed Access | Times Cited: 3
Passive antibody therapy in emerging infectious diseases
Xiaoming Yang
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1117-1134
Closed Access | Times Cited: 3
Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
Young Rock Jang, Yoon Ju Oh, Jin Yong Kim
Current Therapeutic Research (2022) Vol. 96, pp. 100675-100675
Open Access | Times Cited: 5
Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
Yee Gyung Kwak, Je Eun Song, Jieun Kang, et al.
Infection and Chemotherapy (2022) Vol. 54, Iss. 4, pp. 781-781
Open Access | Times Cited: 5
Drug discovery to treat COVID-19 two years after its outbreak
Jianjun Gao, Fusheng Sun
Drug Discoveries & Therapeutics (2021) Vol. 15, Iss. 6, pp. 281-288
Open Access | Times Cited: 7
Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
Hyeong-Jun Noh, Jin Hwa Song, Sin Young Ham, et al.
Medicine (2023) Vol. 102, Iss. 45, pp. e35987-e35987
Open Access | Times Cited: 2
Severe COVID-19: Drugs and Clinical Trials
Hazael Ramiro Ceja-Gálvez, Francisco Israel Renteria-Flores, Ferdinando Nicoletti, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2893-2893
Open Access | Times Cited: 2
Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
Youn Kyung Kee, Hayne Cho Park, Su Jin Yoon, et al.
Kidney Research and Clinical Practice (2024) Vol. 43, Iss. 1, pp. 111-121
Open Access
Treatment of Patients After Lung Transplantation With Covid Infection During Long-Term Follow-Up
Sławomir Żegleń, Adam Nagajewski, Dominik Górski, et al.
Transplantation Proceedings (2024) Vol. 56, Iss. 4, pp. 881-884
Closed Access
A Review of COVID-19 Effective Pharmaceutics Based on Molecular Targets and Single Nucleotide Polymorphisms
Saba Seyedi, Mohammadreza Gerami, Shadan Navid, et al.
Molecular Genetics Microbiology and Virology (2024) Vol. 39, Iss. 4, pp. 315-335
Closed Access
MODERN METHOD OF SARS-CоV-2 COMBAT
N.V. Bobkova, R.A. Poltavtseva, A.V. Chaplygina, et al.
Molekulyarnaya Meditsina (Molecular medicine) (2023) Vol. 21, Iss. 1, pp. 16-24
Closed Access | Times Cited: 1
D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir
Johannes Jungwirth, C. M. Haring, Sarah König, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 6880-6880
Open Access | Times Cited: 2
Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
Jung‐Ick Byun, Jun‐Sang Sunwoo, Kyung Wook Kang, et al.
Journal of the Korean Neurological Association (2022) Vol. 40, Iss. 2, pp. 121-126
Open Access | Times Cited: 1

Scroll to top